Overview

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

Status:
Terminated

Trial end date:
2019-05-31

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to evaluate the efficacy of CINRYZE administered with plasmapheresis, plasma exchange, or immune adsorption treatments and sucrose-free immunoglobulin (IVIg) for the treatment of acute antibody-mediated rejection (AMR) of renal allograft in kidney transplant recipients as measured by the proportion of participants with new or worsening transplant glomerulopathy (TG) at 6 months after treatment initiation.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Antibodies
Complement C1 Inactivator Proteins
Complement C1 Inhibitor Protein